Dishman Carbogen Amcis LtdQ1 FY26
Dishman Carbogen Amcis Ltd Q1 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹173P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
No
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- →The company targets a consolidated revenue CAGR of approximately 15% over the next 2-3 years, higher than the 10-12% growth achieved previously. (Page 28)
- →India business aims to grow significantly, targeting INR 500 crores revenue by FY28, benefiting from tech transfers and multiple projects in the pipeline. (Pages 12, 18, 23)
- →Stand-alone India revenue expected to increase in FY27 versus FY26, with potential to reach or exceed FY25 levels (~INR 400 crores) and grow further in FY28. (Page 19)
- →CDMO segment to maintain approximately 85% share of revenues and grow steadily; marketable molecules about 15%. (Page 16)
- →Margins in both CDMO and marketable molecule segments expected to improve, targeting 25% EBITDA margin by FY28. (Page 15)
- →Growth driven by new contracts, increasing orders, and digital transformation initiatives without major CapEx increase. (Pages 18, 28)
- →French entity's breakeven delayed but expected to improve due to combined drug substance and product offerings. (Page 28)
Margin guidance
Category 3- →Revenue CAGR expected at ~15% over the next 3 years, higher than previous years (Page 28).
- →EBITDA margins targeted to reach 25% by FY28, improving from current levels (Page 15).
- →French subsidiary aims to break even at EBITDA level by FY28, improving losses from EUR 9 million to profitability (Page 21).
- →Indian business expects revenue growth with targets of INR 500 crore+ topline by FY28, with improved profitability (Page 18).
- →Interest cost expected to reduce; net interest cost projected below INR 70 crore in FY28, aiding profit growth (Page 22).
- →Effective consolidated tax rate expected to decline from ~40% in FY27 to ~30% in FY28, and further to 15-20% over three years, enhancing net profits (Page 9).
- →Currency translation gains expected to increase INR denominated profits due to Swiss franc depreciation (Page 30).
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →A long-term external commercial borrowing (ECB) from a promoter entity to the parent company has been approved by the Board, subject to regulatory and shareholder approval.
- →Purpose: To repay high-cost debt in India, reduce overall interest cost, provide flexibility in repayments, and support working capital and CapEx needs.
- →Tenure: 10 years, completely unsecured, allowing release of securities currently provided to banks in India.
- →The refinancing is expected to reduce consolidated interest cost significantly, targeting net interest cost not more than INR 70 crores for FY27.
- →No major CapEx planned except co-investment with a Japanese partner, fully funded by the partner.
- →No explicit mention of equity fundraising during the call.
- →The company aims to decrease net debt by CHF 10-15 million (~INR 150 crore) annually over the next 2-3 years.
Order book
Yes- →The company holds around INR 1,100 to INR 1,200 crores worth of Requests for Proposals (RFPs) in the India business.
- →They expect to convert approximately 30-35% of these RFPs into firm orders.
- →Physical inspection by a large innovator on a product’s active pharmaceutical ingredient is expected soon, which may translate into additional orders.
- →New contracts and orders are in fluid stages; exact quarters of order fulfillment remain uncertain.
- →For India, the target is to scale up revenue by INR 500 crores over the next 12 to 18 months.
- →There is a tech transfer of one of the largest molecules from the Swiss entity to India, expected to increase margins despite giving discounts.
- →Proposals have been made for late-phase and commercial projects in the French entity, with positive effects expected from combined drug substance and drug product offerings.
Capex plans
No- →No major CapEx plans currently, except for co-investment with a Japanese innovator, where 100% of CapEx financing is by the partner (Page 18).
- →Ongoing maintenance CapEx will continue group-wide.
- →Investments planned in digital transformation, including SAP implementation across the group, lab management software, and exploring AI for process efficiencies (Page 18).
- →The recent Swiss manufacturing line went live in Q4 FY25; no significant new fixed assets planned beyond current capacity (Page 9).
- →Some CapEx may be required in the future, but not planned currently; financing sources considered cheap and flexible (Page 26).
- →Tech transfer of a large molecule to India is a key strategic development expected to improve margins and scale India business (Pages 18, 22).
- →Additional working capital and CapEx may be financed through new long-term borrowing approved by the Board (Page 8).
How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Dishman Carbogen Amcis Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
Want more stocks like Dishman Carbogen Amcis Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio